Solid Tumor Cancer Serum

About Solid Tumor Cancer Serum

Human Solid Tumor Cancer Serum for Oncology and Tumour Immunology Research

Our Solid Tumor Cancer Serum is sourced from IRB-consented donors clinically diagnosed with solid tumour malignancy. Each sample is processed and frozen within 24 hours of collection to ensure consistency and high quality for oncology biomarker and tumour immunology research. Solid tumours are neoplastic diseases: the driving biology is clonal proliferation of transformed cells together with the immunosuppressive microenvironment that tumour tissue establishes around itself, and serum carries the soluble trace of both.

Why Serum for Solid Tumor Cancer Research

• Serum is the reference matrix for the established protein tumour markers used clinically across solid tumour types — for example CEA, CA-125, CA 19-9, PSA and AFP, each tied to particular primary sites. Published reference data and most commercial immunoassays are calibrated to serum.
• Tumours shape systemic immunity. Soluble immune checkpoint proteins, including soluble PD-L1, and immunosuppressive mediators such as TGF-beta, IL-10 and VEGF are measurable in serum and are central to understanding response and resistance to checkpoint blockade.
• Cancer-associated systemic inflammation — reflected in IL-6, CRP and acute-phase reactants — is one of the more consistent prognostic signals in advanced solid tumour disease and is well captured in serum.
• An important technical caveat: circulating tumour DNA and other cell-free nucleic acid work is better served by plasma, because the clotting process releases genomic DNA from leukocytes and dilutes the tumour-derived fraction. For liquid biopsy nucleic acid studies, use the plasma product; serum is the right choice for protein and metabolite analytes.
• Serum autoantibody repertoires directed at tumour-associated antigens are a distinct and actively studied class of cancer biomarker that requires a clotted, anticoagulant-free matrix.
• Serum drawn alongside PBMCs or a leukopak from the same donor allows soluble mediators to be interpreted against that donor’s own circulating immune cell composition.

Donor Stratification Available

• Primary tumour site and histological subtype where documented
• Disease stage or extent: early-stage, locally advanced, or metastatic
• Treatment status: treatment-naive, on cytotoxic chemotherapy, on immune checkpoint inhibitor, on targeted therapy, or post-surgical
• Line of therapy and prior treatment exposure
• Receptor, mutation or biomarker status where reported by the treating clinician
• Performance status and relevant comorbidity
• Matched healthy controls available

Product Features

• Collected from clinically confirmed solid tumour cancer donors
• Research Use Only (RUO)
• Processed and frozen within 24 hours of collection
• IRB-approved protocols with documented consent
• Custom aliquot volumes available upon request
• Serial and on-treatment collections available by request

De-identified Donor Data

• Diagnosis confirmation
• Age, sex assigned at birth, and race/ethnicity
• Donor-reported medical history and comorbidities
• Tumour type, stage and treatment history where available
• Additional oncology-specific metadata available on request

Applications

• Protein tumour marker assay development and validation
• Soluble immune checkpoint and cytokine profiling in tumour immunology
• Biomarker discovery for prognosis and treatment response
• Tumour-associated autoantibody and seromic profiling
• Proteomic and metabolomic characterisation of the systemic cancer state
• Extracellular vesicle isolation and cargo analysis
• Diagnostic and companion diagnostic development using disease-state serum as a clinically relevant matrix
• Therapeutic candidate screening and target validation in oncology

Other Solid Tumor Cancer Specimen Types

• Solid Tumor Cancer Plasma
• Solid Tumor Cancer Whole Blood
• Solid Tumor Cancer PBMC
• Solid Tumor Cancer Leukopak

Compliance and Quality Assurance

• IRB-approved and HIPAA-compliant protocols
• Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
• Documentation support available for regulatory review

Ordering & Customization

Solid tumor cancer serum is available in standard and custom volumes. For pricing, availability, or to discuss a stratified cohort by tumour type and stage, email learnmore@sanguinebio.com. For international orders or documentation requirements, please contact us to ensure compatibility with your country’s regulations. To browse serum across all disease states and healthy donors, visit our human serum page.